Common Contracts

25 similar Underwriting Agreement contracts by Coronado Biosciences Inc, Galena Biopharma, Inc., VistaGen Therapeutics, Inc., others

META MATERIALS INC. 83,333,334 Shares of Common Stock Warrants to Purchase up to 83,333,334 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • April 14th, 2023 • Meta Materials Inc. • Semiconductors & related devices

Meta Materials Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to issue and sell to you (the Underwriters”), an aggregate of (i) 83,333,334 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) warrants (the “Firm Warrants”) to purchase up to an aggregate of 83,333,334 shares of Common Stock (the “Firm Warrant Shares”). The respective amounts of the Firm Shares and the Firm Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. The Firm Shares, the Firm Warrants and the Firm Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes to issue and sell to the Underwriters, upon the terms and conditions set forth herein, up to an additional (i) 12,500,000 shares of Common Stock (the “Option Shares,” and together with the Firm Shares, the “Shares”), and/or (ii) warrants (t

AutoNDA by SimpleDocs
CHEMOMAB THERAPEUTICS LTD. Up to [•] American Depositary Shares Or [•] Pre- funded Warrants to Purchase American Depositary Shares And [•] Warrants to Purchase American Depositary Shares UNDERWRITING AGREEMENT
Underwriting Agreement • March 21st, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations

Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (this “Agreement”), for whom you are acting as Representative, if any (the “Representative”), an aggregate of (A) up to [•] (i) American Depositary Shares, or “ADS” (the “Firm Shares”), each representing 20 ordinary shares, no par value per share, of the Company (the “Ordinary Shares”) or (ii) [•] pre-funded warrants to purchase up to [•] ADSs at an exercise price of $0.01 per share, in the form attached hereto as Exhibit A (the “Pre-Funded Warrants”) and (B) [•] warrants, each warrant exercisable for one ADS at an exercise price of $[•] per ADS with a term of five years, in the form attached hereto as Exhibit B (the “Common Warrants” and together with the Pre-funded Warrants, the “Warrants”). The

CHEMOMAB THERAPEUTICS LTD. [•] American Depositary Shares [•] Warrants UNDERWRITING AGREEMENT
Underwriting Agreement • February 21st, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations

Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (this “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) [•] American Depositary Shares (the “Shares”), each representing 20 ordinary shares, no par value per share, of the Company (the “Ordinary Shares” and the American Depositary Shares, the “ADSs”) and (ii) [•] warrants, each warrant exercisable for one ADS at an exercise price of $[•] per ADS with a term of five years, in the form attached hereto as Exhibit A (the “Warrants”). The respective amounts of the Shares and Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.

MODULAR MEDICAL, INC. [____] Shares of Common Stock [_____] Warrants UNDERWRITING AGREEMENT
Underwriting Agreement • February 14th, 2022 • Modular Medical, Inc. • Surgical & medical instruments & apparatus • New York

Modular Medical, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (the “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) [________] shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) warrants, each warrant exercisable for one share of Common Stock at an exercise price of $[_____] per share with a term of five years (the “Warrants”). The respective amounts of the Shares and Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.

MODULAR MEDICAL, INC. [____] Shares of Common Stock [_____] Warrants UNDERWRITING AGREEMENT
Underwriting Agreement • February 7th, 2022 • Modular Medical, Inc. • Surgical & medical instruments & apparatus • New York

Modular Medical, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (the “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) [________] shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) warrants, each warrant exercisable for one share of Common Stock at an exercise price of $[_____] per share with a term of five years (the “Warrants”). The respective amounts of the Shares and Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.

CINGULATE INC. [____] Units UNDERWRITING AGREEMENT
Underwriting Agreement • November 30th, 2021 • Cingulate Inc. • Pharmaceutical preparations

Cingulate Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (the “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of [________] units (the “Firm Units”), with each Firm Unit consisting of one share of common stock, $0.0001 par value per share (the “Common Stock”) of the Company (the “Firm Shares”), and a warrant to purchase one share of Common Stock, at an exercise price of $[_____] per share and with a term of five (5) years (the “Firm Warrants”). The respective amounts of the Firm Units to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase from the Company, for the purpose of covering over-allotments in connection with the sale of t

VistaGen Therapeutics, Inc. 10,000,000 Shares of Common Stock Warrants to Purchase up to 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 13th, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York

VistaGen Therapeutics, Inc., a Nevada corporation (the "Company") proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the "Underwriters"), for whom you are acting as Representative (the “Representative”), an aggregate of (i) 10,000,000 shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 10,000,000 shares of Common Stock (the “Warrant Shares”). Each Share is being sold together with a Warrant to purchase one Warrant Share. The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The Shares and the Warrants will be issued separately, but will be purchased together in the offering. The respective amounts of the Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.

VistaGen Therapeutics, Inc. [_] Shares of Common Stock [_] Warrants to Purchase up to [_] Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 7th, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York

VistaGen Therapeutics, Inc., a Nevada corporation (the "Company") proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the "Underwriters"), for whom you are acting as Representative (the “Representative”), an aggregate of (i) [_] shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), and (ii) warrants (the “Warrants”) to purchase up to an aggregate of [_] shares of Common Stock (the “Warrant Shares”). Each Share is being sold together with 1.0 Warrant to purchase one Warrant Share. The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The Shares and the Warrants will be issued separately, but will be purchased together in the offering. The respective amounts of the Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.

Ordinary Shares ENTERA BIO LTD. Ordinary Shares FORM OF UNDERWRITING AGREEMENT
Underwriting Agreement • November 20th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances) • New York

Entera Bio Ltd., an Israeli company (the "Company"), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the "Underwriters") named on Schedule I to this Underwriting Agreement (the "Agreement"), for whom you are acting as Representative (the "Representative"), an aggregate of ________ ordinary shares (the "Firm Shares") of the Company, NIS 0.01 par value per share (the "Ordinary Shares"). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional ___________ Ordinary Shares (the "Company Option Shares") from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the "Shares."

VistaGen Therapeutics, Inc. 1,371,430 Shares of Common Stock Series A1 Warrants to Purchase up to 1,388,931 Shares of Common Stock and Series A2 Warrants to Purchase up to 503,641 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 31st, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York

VistaGen Therapeutics, Inc., a Nevada corporation (the "Company") proposes, subject to the terms and conditions contained herein, to sell to you (the "Underwriter"), an aggregate of (i) 1,371,430 shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), (ii) Series A1 warrants (the “Series A1 Warrants”) to purchase up to an aggregate of 1,388,931 shares of Common Stock (the “Series A1 Warrant Shares”) and (iii) Series A2 warrants (the “Series A2 Warrants”, and collectively, with the Series A1 Warrants, the “Warrants”) to purchase an aggregate of 503,641 shares of Common Stock (the “Series A2 Warrant Shares,” and collectively, with the Series A1 Warrant Shares, the “Warrant Shares”). Each Share is being sold together with 1.0128 Series A1 Warrants, each whole Series A1 Warrant to purchase one Series A1 Warrant Share, and 0.3672 of a Series A2 Warrant, each Whole Series A2 Warrant to purchase one Series A2 Warrant Share. The Shares, the Warrant

Actinium Pharmaceuticals, Inc. 21,500,000 Shares of Common Stock and Warrants to Purchase up to 18,275,000 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • July 28th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) 21,500,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 18,275,000 shares of Common Stock (the “Warrant Shares”). Each Share is being sold together with .85 of a Warrant to purchase one Warrant Share. The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The Shares and the Warrants will be issued separately, but will be purchased together in the offering. The respective amounts of the Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.

Shares AIR INDUSTRIES GROUP Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 19th, 2017 • Air Industries Group • Aircraft parts & auxiliary equipment, nec • New York
UNDERWRITING AGREEMENT
Underwriting Agreement • February 10th, 2017 • Galena Biopharma, Inc. • Pharmaceutical preparations

Galena Biopharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you (the “Underwriter”) an aggregate of (i) 17,000,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and (ii) warrants to purchase 17,000,000 shares of Common Stock on the terms and conditions set forth in the Warrant Agreement (as defined herein) (the “Warrants”, and together with the Shares, the “Securities”). All of the Securities are to be issued and sold by the Company. The shares of Common Stock underlying the Warrants are referred to herein as the “Warrant Shares.”

EXECUTION VERSION 3,000,000 Shares ENERGY FOCUS, INC. Common Stock UNDERWRITING AGREEMENT September 11, 2015 Oppenheimer & Co. Inc., as Representative of the several Underwriters named in Schedule I hereto c/o Oppenheimer & Co. Inc. 85 Broad Street...
Underwriting Agreement • September 14th, 2015 • Energy Focus, Inc/De • Electric lighting & wiring equipment • Ohio
24,358,974 Shares GALENA BIOPHARMA, INC. Common Stock and Warrants to Purchase up to 12,179,487 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • March 16th, 2015 • Galena Biopharma, Inc. • Pharmaceutical preparations • New York

In addition, the undersigned hereby waives, from the date hereof until the expiration of the Lock-Up Period, any and all rights, if any, to request or demand registration pursuant to the Securities Act of any Securities of Common Stock or securities convertible into or exercisable or exchangeable for any equity securities of the Company that are registered in the name of the undersigned or that are Beneficially Owned Securities. In order to enable the aforesaid covenants to be enforced, the undersigned hereby consents to the placing of legends and/or stop transfer orders with the transfer agent of the Common Stock with respect to any Securities of Common Stock, securities convertible into or exercisable or exchangeable for any equity securities of the Company or Beneficially Owned Securities.

UNDERWRITING AGREEMENT
Underwriting Agreement • September 13th, 2013 • Galena Biopharma, Inc. • Pharmaceutical preparations • New York

Galena Biopharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) 17,500,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) and (ii) warrants to purchase 6,125,000 shares of Common Stock (the “Firm Warrants”, and together with the Firm Shares, the “Firm Securities”). All of the Firm Securities are to be issued and sold by the Company. The respective amounts of the Firm Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional (i) 2,625,000 shares of Common Stock (the “Option Shares”, and together with the Firm Shares,

40,000,000 Shares of Common Stock ($0.01 par value per Share) and Warrants to Purchase up to 30,000,000 Shares of Common Stock MannKind Corporation UNDERWRITING AGREEMENT
Underwriting Agreement • October 19th, 2012 • Mannkind Corp • Pharmaceutical preparations

MannKind Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you, Jefferies & Company, Inc. (“Jefferies”) and Piper Jaffray & Co. (“Piper”), acting as representatives (together, the “Representatives”) of the underwriters named on Schedule I to this Agreement (the “Underwriters”), an aggregate of (i) 40,000,000 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and (ii) warrants of the Company, in the form set forth in Exhibit F hereto, to purchase 30,000,000 shares of Common Stock (the “Warrants”). Each share of Common Stock is being sold together with a Warrant to purchase 0.75 of a share of Common Stock at an exercise price of $2.60 per share. The shares of Common Stock issuable upon exercise of the Warrants are called the “Warrant Shares,” and the Warrant Shares, together with the Warrants and the Shares, are called the “Securities.” The 40,000,000 Shares to

5,000,000 Shares CORONADO BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 26th, 2012 • Coronado Biosciences Inc • Pharmaceutical preparations • New York

Coronado Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 5,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 750,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

4,600,000 Shares CORONADO BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 21st, 2012 • Coronado Biosciences Inc • Pharmaceutical preparations • New York

Coronado Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 4,600,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 690,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

2,000,000 Shares CORONADO BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 12th, 2012 • Coronado Biosciences Inc • Pharmaceutical preparations • New York

Coronado Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 2,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 300,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

31,250,000 Units Each Unit Consisting of One Share of Common Stock ($0.01 par value per Share) and A Warrant to Purchase 0.6 of a Share of Common Stock MannKind Corporation UNDERWRITING AGREEMENT
Underwriting Agreement • February 6th, 2012 • Mannkind Corp • Pharmaceutical preparations

MannKind Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you, Jefferies & Company, Inc. (“Jefferies”), Piper Jaffray & Co. (“Piper”) and Cowen and Company, LLC acting as representatives (together, the “Representatives”) of the underwriters named on Schedule I to this Agreement (the “Underwriters”), an aggregate of 31,250,000 units (the “Units”), each of which

Shares China Shengda Packaging Group Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • November 17th, 2010 • China Shengda Packaging Group Inc. • Paperboard containers & boxes • New York

China Shengda Packaging Group Inc., a Nevada corporation (the “Company”) and the person listed on Schedule II hereto (the “Selling Stockholder”), propose, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). Of the Firm Shares, are to be issued and sold by the Company and are to be sold by the Selling Stockholder. The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of

AutoNDA by SimpleDocs
2,750,000 Shares CHANGING WORLD TECHNOLOGIES, INC. Common Stock, $0.01 par value per share FORM OF UNDERWRITING AGREEMENT
Underwriting Agreement • February 6th, 2009 • Changing World Technologies, Inc. • Industrial organic chemicals • New York

Changing World Technologies, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained in this Underwriting Agreement (the “Agreement”), to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 2,750,000 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 412,500 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

UNDERWRITING AGREEMENT
Underwriting Agreement • May 2nd, 2007 • Pharmacopeia Drug Discovery Inc • Services-commercial physical & biological research • New York
25,000,000 Shares COEUR D’ALENE MINES CORPORATION Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • November 22nd, 2004 • Coeur D Alene Mines Corp • Gold and silver ores • New York

Coeur d’Alene Mines Corporation, an Idaho corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 25,000,000 shares (the “Firm Shares”) of the Company’s common stock, $1.00 par value per share (the “Common Stock”). All of the Firm Shares are to be issued and sold by the Company. The amount of the Firm Shares to be purchased by each of the Underwriters is set forth opposite its name on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 2,500,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!